Zika Clinical Trials
Here are the 0 most popular medical studies for zika
Frequently Asked Questions
Introduction to zika
What are the top hospitals conducting zika research?
Despite the relatively limited number of clinical trials for zika virus, several hospitals across different locations are actively contributing to research and intervention efforts. In Oakland Park, Florida, CenExel Research Centers of America is conducting one ongoing zika trial. Similarly, Velocity Clinical Research in Meridian, Idaho; AMR East Wichita (formerly known as Heartland Associates East Wichita) in Wichita, Kansas; AMR Lexington (formerly Central Kentucky, Florida, CenExel Research Centers of America is conducting one ongoing zika trial. Similarly, Velocity Clinical Research in Meridian, Idaho; AMR East Wichita (formerly known as Heartland Associates East Wichita) in Wichita, Kansas; AMR Lexington (formerly Central Kentucky Research Associates) in Lexington, Kentucky; and Alliance for Multispecialty Research in Kansas City are all engaged in one active zika trial each. While these hospitals may not have a history of completed zika trials yet due to the recent emergence of this disease and the challenges it poses globally, their dedicated involvement underscores the urgency to find solutions and mitigate the impact of this infectious threat. Collaboration between medical institutions across various regions brings hope that collectively we can combat zika virus effectively by advancing scientific knowledge and developing effective interventions to protect vulnerable populations from its detrimental effects.
Which are the best cities for zika clinical trials?
When it comes to zika clinical trials, a few cities have emerged as key players in advancing research and finding effective treatments. Atlanta, Georgia leads the way with 2 active trials focused on studying the INTERCEPT Blood System for Red Blood Cells among other interventions. Following closely behind are Oakland Park, Florida; Meridian, Idaho; Wichita, Kansas; and Lexington, Kentucky - all hosting 1 active trial each investigating the potential of Purified Inactivated Zika Virus, Kentucky - all hosting 1 active trial each investigating the potential of Purified Inactivated Zika Virus Vaccine (PIZV) along with other relevant approaches. These cities offer individuals affected by zika virus access to cutting-edge clinical trials that contribute to improved understanding and management of this public health concern.
Which are the top treatments for zika being explored in clinical trials?
Clinical trials are actively exploring potential treatments for Zika virus, with a focus on two promising options. ZIKV-SJRP/2016-184 Strain is currently being evaluated in one active trial and has been listed since 2022. Another contender, mRNA-1893, is also under investigation in one ongoing trial and was first introduced in 2019. These innovative treatments offer hope in the fight against Zika, as researchers strive to find effective interventions for this global health concern.
What are the most recent clinical trials for zika?
Recent clinical trials are shedding light on potential breakthroughs in the fight against Zika virus. One notable study focuses on ZIKV-SJRP/2016-184, a strain specific to zika. This Phase 1 trial aims to assess its effectiveness and safety for future treatment options. Another promising development is mRNA-1893, currently in Phase 2, which holds great potential as a therapeutic option against zika. Lastly, the INTERCEPT Blood System's Phase 3 trial explores the efficacy of using this system with red blood cells to help prevent transmission of zika through blood transfusions. These trials represent important steps forward in our understanding and management of this viral infection that has posed significant global health challenges.
What zika clinical trials were recently completed?
Recently, several clinical trials investigating potential treatments for Zika virus have reached completion. These trials aim to address the urgent need for effective therapies against this viral infection. One notable trial was conducted by the National Institute of Allergy and Infectious Diseases (NIAID), which concluded in October 2021. In addition, a separate study sponsored by an international consortium reached its conclusion in September 2021. The completion of these trials marks significant progress in our understanding and management of Zika virus, providing hope for improved interventions and outcomes for those affected by this disease.